VivoSeq
Oncology

Recurrent Mantle Cell Lymphoma

4

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Recurrent Mantle Cell Lymphoma is an early-stage landscape with 4 programs across 3 companies. The most active players are Roche, Merck & Co., Gilead.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 24

Nemtabrutinib

Merck & Co.

Brexucabtagene Autoleucel

Gilead

Glofitamab

Roche

Obinutuzumab

Roche

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

4programs
Monoclonal antibody250%
Small molecule125%
Cell therapy125%

Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Not yet recruiting1 · 50%

Clinical Trials

Trial Activity

A Phase II Study of Glofitamab for Relapsed/Refractory Mantle Cell Lymphoma in Patients Previously Treated With CD19-Directed CAR T-Cell Therapy
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT07003295·20 enrolled
A Phase 2 Trial of Nemtabrutinib in Combination With Brexu-cel for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Not yet recruiting·VVanderbilt-Ingram Cancer Center·Phase 2·NCT07673367·25 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)